schliessen

Filtern

 

Bibliotheken

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence

We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK si... Full description

Journal Title: Sci Rep 2016, Vol.6(1), pp.22976-22976
Main Author: Chen, Wei
Other Authors: Xiao, Weikai , Zhang, Kunsong , Yin, Xiaoyu , Lai, Jiaming , Liang, Lijian , Chen, Dong
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 2045-2322 ; DOI: 10.1038/srep22976
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: palgrave_j10.1038/srep22976
title: Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
format: Article
creator:
  • Chen, Wei
  • Xiao, Weikai
  • Zhang, Kunsong
  • Yin, Xiaoyu
  • Lai, Jiaming
  • Liang, Lijian
  • Chen, Dong
subjects:
  • Biology
ispartof: Sci Rep, 2016, Vol.6(1), pp.22976-22976
description: We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent manner in PLC/PRF/5 and MHCC97H cell lines. Decreased expression levels of 6 genes after sorafenib treatment suggested a robust inhibitory impact of sorafenib on MAPK signaling in HCC cells. c-Jun and p-c-Jun expression levels were inversely correlated with the efficacy of sorafenib; a high expression level of p-c-Jun was associated with resistance to sorafenib and poor overall survival in patients with clinical HCC. p-c-Jun may act as a biomarker for predicting responses of sorafenib treatment, thus advocating targeting of JNK/c-Jun signaling as an optimal therapeutic strategy in a subset of HCC.
language: eng
source:
identifier: ISSN: 2045-2322 ; DOI: 10.1038/srep22976
fulltext: fulltext
issn:
  • 2045-2322
  • 20452322
url: Link


@attributes
ID868695653
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1038/srep22976
sourceidpalgrave_j
recordidTN_palgrave_j10.1038/srep22976
sourcesystemOther
pqid1898725806
display
typearticle
titleActivation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
creatorChen, Wei ; Xiao, Weikai ; Zhang, Kunsong ; Yin, Xiaoyu ; Lai, Jiaming ; Liang, Lijian ; Chen, Dong
ispartofSci Rep, 2016, Vol.6(1), pp.22976-22976
identifierISSN: 2045-2322 ; DOI: 10.1038/srep22976
descriptionWe determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent manner in PLC/PRF/5 and MHCC97H cell lines. Decreased expression levels of 6 genes after sorafenib treatment suggested a robust inhibitory impact of sorafenib on MAPK signaling in HCC cells. c-Jun and p-c-Jun expression levels were inversely correlated with the efficacy of sorafenib; a high expression level of p-c-Jun was associated with resistance to sorafenib and poor overall survival in patients with clinical HCC. p-c-Jun may act as a biomarker for predicting responses of sorafenib treatment, thus advocating targeting of JNK/c-Jun signaling as an optimal therapeutic strategy in a subset of HCC.
languageeng
source
subjectBiology;
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Chen, Wei
1Xiao, Weikai
2Zhang, Kunsong
3Yin, Xiaoyu
4Lai, Jiaming
5Liang, Lijian
6Chen, Dong
titleActivation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
descriptionWe determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent manner in PLC/PRF/5 and MHCC97H cell lines. Decreased expression levels of 6 genes after sorafenib treatment suggested a robust inhibitory impact of sorafenib on MAPK signaling in HCC cells. c-Jun and p-c-Jun expression levels were inversely correlated with the efficacy of sorafenib; a high expression level of p-c-Jun was associated with resistance to sorafenib and poor overall survival in patients with clinical HCC. p-c-Jun may act as a biomarker for predicting responses of sorafenib treatment, thus advocating targeting of JNK/c-Jun signaling as an optimal therapeutic strategy in a subset of HCC.
general
0English
110.1038/srep22976
2Palgrave Macmillan Journals
sourceidpalgrave_j
recordidpalgrave_j10.1038/srep22976
issn
02045-2322
120452322
rsrctypearticle
creationdate2016
addtitleSci Rep
searchscopepalgrave_j
scopepalgrave_j
lsr30VSR-Enriched:[pages, subject, pqid]
sort
titleActivation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
authorChen, Wei ; Xiao, Weikai ; Zhang, Kunsong ; Yin, Xiaoyu ; Lai, Jiaming ; Liang, Lijian ; Chen, Dong
facets
frbrgroupid-3989128693364635761
frbrtype5
newrecords
020180122
120180122
languageeng
creationdate2016
collectionPalgrave Macmillan Journals
prefilterarticles
rsrctypearticles
creatorcontrib
0Chen, Wei
1Xiao, Weikai
2Zhang, Kunsong
3Yin, Xiaoyu
4Lai, Jiaming
5Liang, Lijian
6Chen, Dong
jtitleSci Rep
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Chen
1Xiao
2Zhang
3Yin
4Lai
5Liang
aufirst
0Wei
1Weikai
2Kunsong
3Xiaoyu
4Jiaming
5Lijian
6Dong
au
0Chen, Wei
1Xiao, Weikai
2Zhang, Kunsong
3Yin, Xiaoyu
4Lai, Jiaming
5Liang, Lijian
6Chen, Dong
atitleActivation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
jtitleSci Rep
date20169
risdate20169
volume6
issue1
spage22976
epage22976
issn2045-2322
formatjournal
genrearticle
ristypeJOUR
abstractWe determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent manner in PLC/PRF/5 and MHCC97H cell lines. Decreased expression levels of 6 genes after sorafenib treatment suggested a robust inhibitory impact of sorafenib on MAPK signaling in HCC cells. c-Jun and p-c-Jun expression levels were inversely correlated with the efficacy of sorafenib; a high expression level of p-c-Jun was associated with resistance to sorafenib and poor overall survival in patients with clinical HCC. p-c-Jun may act as a biomarker for predicting responses of sorafenib treatment, thus advocating targeting of JNK/c-Jun signaling as an optimal therapeutic strategy in a subset of HCC.
pubNature Publishing Group UK
doi10.1038/srep22976
pages22976